Malignancy hypercalcemia: evaluation of parathyroid function and response to treatment

Area of Science:

• Endocrinology
• Oncology
• Clinical Chemistry

Background:

• Malignancy-associated hypercalcemia is a common complication of cancer.
• Distinguishing hypercalcemia of malignancy from primary hyperparathyroidism is crucial for appropriate management.
• Parathyroid hormone (PTH) assays are used to differentiate these conditions.

Purpose of the Study:

• To compare the diagnostic utility of intact PTH and midregion PTH assays in patients with malignancy-associated hypercalcemia.
• To evaluate the parathyroid response to bisphosphonate treatment in these patients.
• To assess the impact of renal insufficiency on PTH assay performance.

Main Methods:

• Serum intact PTH and midregion PTH levels were measured using immunoradiometric assay (IRMA) and radioimmunoassay (RIA), respectively.
• Measurements were taken at baseline and after intravenous bisphosphonate treatment in 53 patients with malignancy-associated hypercalcemia.
• Data were analyzed to assess assay performance in detecting hyperparathyroidism and monitoring treatment response.

Main Results:

• Intact PTH assays effectively suppressed below 25 pg/ml in 51 out of 53 patients, confirming nonparathyroid hypercalcemia.
• Midregion PTH assays were less sensitive but supported the diagnosis in 44 out of 49 cases.
• Intact PTH assay demonstrated better diagnostic accuracy in patients with renal insufficiency, where midregion assays showed less suppression.

Conclusions:

• Intact PTH assays are more reliable than midregion assays for diagnosing hypercalcemia of malignancy, particularly in the presence of renal insufficiency.
• Hypercalcemia more effectively suppresses intact PTH secretion compared to PTH fragments.
• Parathyroid glands can rapidly increase PTH secretion following correction of chronic hypercalcemia.